bioihbjkbjnl/mcl2 huggingface dataset:
Comparison of Difference Histamine Concentration (1, 5 and 10 mg/ml) for Skin Prick Test Positive Control
Condition: Immediate Hypersensitivity
MeSH terms: Hypersensitivity; Hypersensitivity, Immediate
Study type: Interventional

Summary: 
      Skin prick test (SPT) was used for diagnostic test for type 1 hypersensitivity. The efficacy
      and safety of SPT were proved. The positive control of SPT is histamine.

      In Thailand, the most common concentration of histamine for SPT is 10 mg/ml. However, in some
      practice they use other concentration (1, 2.5 mg/ml).

      This study will find the proper concentration of histamine for positive control use in SPT.
    

Detailed description: 
      Appropriate concentration of histamine positive control is important in interpretation the
      result of skin prick test.
    

Intervention name(s): SPT
Intervention type(s): Procedure
Intervention description(s): SPT of histamine concentration 1, 5 and 10 mg/ml
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Types of Intimate Partner Violence and Women's Health
Condition: Domestic Violence
Study type: Observational

Summary: 
      This study uses data from 29,990 women from 12 different countries collected by the WHO
      multi-country study on women's health and domestic violence to capture the effect of
      different types, frequency and timing of IPV on self-reported health, symptoms and suicidal
      behaviours.
    

Detailed description: 
      Intimate partner violence (IPV) has detrimental effects on physical and mental health, risks
      to children and is associated with wider societal and healthcare costs. Previous analysis of
      the WHO multi-country study on women's health and domestic violence found significant
      associations between physical and sexual IPV and self-reported ill-health, symptomatology and
      suicidal behaviours.

      Real experience of IPV can comprise different combinations of emotional, physical and sexual
      abuse, and different timings and frequencies of these. A more nuanced testing of exposure to
      these different combinations of IPV and associations with health is needed.

      This study uses data from 29,990 women from 12 different countries collected by the WHO
      multi-country study on women's health and domestic violence to capture the effect of
      different combination types, frequency and timing of IPV on self-reported health, symptoms
      and suicidal behaviours.
    

Observational model: Other
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        This study consists of further analysis of 29,990 interviews conducted with women in 12
        different countries coordinated by the World Health Organisation. They report in most sites
        around 1500 women between 15 and 49 years old were interviewed. Countries included were
        Bangladesh, Brazil, Cambodia, Ethiopia, Japan, Maldives, Namibia, Peru, Samoa, Serbia and
        Montenegro, Thailand and the United Republic of Tanzania.
      
Keywords: Intimate Partner Violence
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
Condition: Cannabis Dependence
MeSH terms: Marijuana Abuse
Study type: Interventional
Phase: Phase 2

Summary: 
      Cannabis dependence is associated with changes in the brain's cannabinoid system. When
      cannabis dependent individuals try to quit using cannabis, some of them experience problems
      that make it difficult for them to achieve and maintain abstinence. Therefore, reducing the
      problems related to quitting cannabis may facilitate abstinence. One way to do this is by
      harnessing the brain's capacity to make its own cannabis-like substances - endocannabinoids.
      One of the main endocannabinoids is anandamide. The study is based on the hypothesis that the
      problems related to quitting cannabis use will be reduced by increasing the brain levels of
      anandamide. Furthermore, by reducing the problems related to quitting cannabis, people will
      be less likely to relapse. Brain anandamide levels will be increased by blocking the
      breakdown of anandamide using a fatty acid amide hydrolase inhibitor (FAAH-I). The effects of
      a novel FAAH-I cannabis withdrawal and relapse in cannabis dependent subjects will be studied
      in a double-blind, randomized, controlled, proof-of-concept study. Cannabis-dependent
      subjects will receive placebo or the FAAH-inhibitor PF-04457845 in a 2:1 randomization. The
      trial consists of a 1 week inpatient stay to achieve abstinence, a 3 week outpatient
      treatment phase. Cannabis withdrawal will be measured during the inpatient phase. Cannabis
      use and urinary THC-COOH levels will be measured during the entire study. The treatment phase
      will be followed by a safety follow up phase of 8 weeks.
    


Intervention name(s): PF-04457845; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Study medication will be administered at 4mg by mouth daily for four weeks.; Sugar pill
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Maxillary Sinus Irrigation in the Management of Chronic Rhinosinusitis
Condition: Sinusitis
MeSH terms: Sinusitis
Study type: Interventional

Summary: 
      The purpose of this study is to evaluate the effectiveness of maxillary sinus saline
      irrigation in conjunction with systemic antibiotic therapy versus systemic antibiotic therapy
      alone in the management of chronic rhinosinusitis, a prospective randomized controlled trial.
    

Detailed description: 
      Effectiveness of maxillary sinus saline irrigation in conjunction with systemic antibiotic
      therapy versus systemic antibiotic therapy alone in the management of chronic rhinosinusitis.
      A prospective randomized controlled trial is being conducted in Carmel Medical Center, Haifa,
      Israel. Patients are being randomized into one of two arms. One arm receives sinus irrigation
      with saline in conjunction with IV antibiotics, the control arm receives the same regimen of
      IV antibiotics without the sinus irrigation. Quality of life, CT scans and nasal endoscopy
      parameters are collected before and after treatment.
    

Intervention name(s): Maxillary Sinus Irrigation; IV Amoxicillin and Clavulanate acid
Intervention type(s): Procedure; Drug
Intervention description(s): Twice a day irrigation with 100cc saline for 4 days; IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
Intervention MeSH terms: Amoxicillin; Clavulanic Acid; Clavulanic Acids
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: chronic rhinosinusitis; sinus irrigation
An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants
Condition: Sepsis
Study type: Interventional
Phase: Phase 1

Summary: 
      This is a safety and pharmacokinetic study of single-dose daptomycin in infants > 48 hours
      and < 120 days of age with suspected systemic infections. The investigators will enroll a
      total of 24 infants in 4 gestational age/postnatal age cohorts. Interim analyses will be
      performed after 3 infants are enrolled in each cohort. The investigators anticipate that 6
      mg/kg of daptomycin will yield an AUC <740 mch*hr/mL.
    


Intervention name(s): Daptomycin
Intervention type(s): Drug
Intervention description(s): single dose of 6 mg/kg of daptomycin
Intervention MeSH terms: Daptomycin
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Infants; Daptomycin
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Condition: Kidney Cancer
MeSH terms: Kidney Neoplasms; Carcinoma, Renal Cell
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor.

      PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with
      locally recurrent or metastatic kidney cancer.
    

Detailed description: 
      OBJECTIVES:

      Primary

        -  Determine the efficacy of sunitinib malate in patients with locally recurrent or
           metastatic papillary renal cell carcinoma.

      OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats
      every 6 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed at 28 days and every 2 months
      thereafter.
    

Intervention name(s): sunitinib malate
Intervention type(s): Drug
Intervention MeSH terms: Sunitinib
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: recurrent renal cell cancer; stage IV renal cell cancer
MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction
Condition: Coronary Microvascular Dysfunction; Ischemic Non-Obstructive Coronary Artery Disease
MeSH terms: Coronary Artery Disease
Study type: Observational

Summary: 
      According to the Women's Ischemic Syndrome Evaluation database, there are approximately 3 to
      4 million women and men who present with signs and symptoms that are suggestive of myocardial
      ischemia, however they have no obstructive coronary artery disease (INOCA). INOCA is defined
      as patients presenting with signs or symptoms of ischemia but no obstructive artery disease.
      Women are more likely than men to die from cardiovascular disease and more likely to present
      with no obstructive coronary artery disease. Patients who present with signs and symptoms
      suggestive of INOCA/MINOCA are also presenting with Coronary Microvascular Dysfunction (CMD).
      Coronary Microvascular Dysfunction is a dysfunction in the epicardial and/or microvascular
      endothelial and/or nonendothelial that limits myocardial perfusion. Today, there is no
      routinely offered/available noninvasive test that is used for the diagnosis of CMD,
      significantly hindering the ability to identify the disease in the standard of care.
      Magenetocardiography (MCG) has the opportunity to use its noninvasive imaging techniques to
      provide early management of CMD. Magnetocardiography (MCG) is a noninvasive imaging modality
      that has been extensively studied, over the past several decades, as a diagnostic imaging
      solution for various forms of cardiovascular disease. MCG measures the magnetic field that
      arises from the electrical activity of the heart's pacemaker activity, the very same activity
      which yield surface electric field potentials as measured by the electrocardiogram. Since MCG
      is a functional assessor of repolarization heterogeneity, it is hypothesized that MCG may be
      a useful frontline diagnostic to identify CMD in patients who would otherwise have normal
      coronary CT angiograms and/or stress tests. The proposed study intends to study the
      diagnostic accuracy of MCG in this population, with the goal of providing early and
      noninvasive insights for management of CMD. There will be a 12-month duration of the study
      where the investigators propose to collect MCG scans from approximately 150 patients who
      present to the Genetesis facility for a 15-minute CardioFlux scan appointment.
    


Intervention name(s): CardioFlux
Intervention type(s): Device
Intervention description(s): Not an intervention
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        All patients presenting with signs and symptoms of chest pain that prompted further
        evaluation by either a heart angiogram or a scan of the heart (coronary CT angiogram)
        within the previous 5 years.
      
Keywords: INOCA; Magnetocardiography; CardioFlux; MCG; Coronary Microvascular Dysfunction
Antipsychotic Therapy and First Episode
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional
Phase: Phase 4

Summary: 
      For schizophrenic patients who remained in remission while on maintenance medication, there
      may come a point in time when the relative risk for relapse become so low that
      discontinuation of therapy can be considered. This study is to investigate whether that point
      in time is reached in 12 months following the first episode illness. Moreover, it also aims
      to identify other predictors of relapse as well as to evaluate the costs and benefits of
      maintenance therapy.
    


Intervention name(s): Quetiapine
Intervention type(s): Drug
Intervention MeSH terms: Quetiapine Fumarate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy
Condition: Prostatic Hypertrophy, Benign
MeSH terms: Prostatic Hyperplasia; Hypertrophy
Study type: Interventional
Phase: Phase 2

Summary: 
      The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin.
      In the presence of hemoglobin, its application causes vaporization of the tissue and this
      effect depends on the concentration of hemoglobin in the respective tissue. Therefore,
      increase of blood-flow in the tissue (here: prostate gland) should exert better efficacy of
      the laser application and consequently shortening of the required duration of laser
      application.
    


Intervention name(s): Vardenafil (Levitra, BAY38-9456); Placebo
Intervention type(s): Drug; Drug
Intervention description(s): One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.; One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
Intervention MeSH terms: Vardenafil Dihydrochloride
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Dermacyd Femina Delicata (Lactic Acid)- Photo Dermatological Evaluation of the Irritation and Sensitivity Potential
Condition: Hygiene
MeSH terms: Hypersensitivity
Study type: Interventional
Phase: Phase 3

Summary: 
      To prove the absence of photo irritation and photo sensitivity potential of the product
      Dermacyd Femina Delicata.
    


Intervention name(s): Lactic acid (Dermacyd Femina Delicata)
Intervention type(s): Drug
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Letrozole or Combined Metformin Clomiphene Citrate (CC) for Women With CC Resistant Polycystic Ovary Syndrome
Condition: Polycystic Ovary Syndrome
MeSH terms: Polycystic Ovary Syndrome; Syndrome
Study type: Interventional

Summary: 
      The purpose of this study is to compare and determine the efficacy of letrozole
      administration to that of combined metformin and Clomiphene in infertile women with
      polycystic ovary syndrome (PCOS) not responding to treatment with Clomiphene alone.
    

Detailed description: 
      Withdrawal bleeding was achieved using 10 mg of dydrogesterone tablets for 10 days before
      stimulation. In the letrozole group, 2.5 mg of letrozole oral tablets (Femara; Novartis
      Pharma Services, Switzerland) daily from day 3 of the menses for 5 days, whereas all patients
      in the combined metformin-CC group) received metformin HCl [Cidophage®; Chemical Industries
      Development(CID), Cairo, Egypt], 500 mg three times daily for 6-8 weeks. Then after the end
      of this period, they received 150 mg CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)
      for 5 days starting from day 3 of menstruation. Patients continued treatment for three
      successive cycles using the same protocol. Metformin was stopped only when pregnancy was
      documented.
    

Intervention name(s): Letrozole tablets (Femara; Novartis Pharma, Switzerland); metformin HCl (Cidophage®; CID,Cairo, Egypt); CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)
Intervention type(s): Drug; Drug; Drug
Intervention description(s): 2.5 mg letrozole daily from day 3 of the menses for 5 days; metformin HCl 1500 daily for 6-8 weeks; 150 mg CC for 5 days starting from day 3 of menstruation
Intervention MeSH terms: Metformin; Letrozole
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Polycystic ovary syndrome; clomiphene resistance; letrozole
Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth
Condition: Transgendered Persons
Study type: Observational

Summary: 
      This study plans to learn more about puberty blockers and cross (testosterone and estradiol).
      There is not much known about how these medications affect hormone levels, heart health and
      overall general health in young transgender individuals.
    

Detailed description: 
      This study plans to learn more about puberty blockers and cross (testosterone and estradiol).
      There is not much known about how these medications affect hormone levels, heart health and
      overall general health in young transgender individuals.
    

Observational model: Other
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Transgender youth ages 9 to 21 years of age who have been on a Gonadotropin-releasing
        hormone (GnRH) agonist or cross-sex hormones for at least three months
      
Biospecimen description: 
      Blood
Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)
Condition: Electronic Cigarette Use
Study type: Interventional

Summary: 
      This study aims to better understand how e-cigarettes (ECIG) nicotine flux impacts several
      behavioral economic measures of abuse liability.
    


Intervention name(s): Tobacco product administration and assessment
Intervention type(s): Other
Intervention description(s): 4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Single (Participant)
Primary purpose: Basic Science
Keywords: Electronic Cigarette; Nicotine Flux
Effects of a 12-week VR Intervention on the Functional Fitness of Adults of Different Age Ranges
Condition: Functional Fitness; Virtual Reality
Study type: Interventional

Summary: 
      This study aimed to evaluate the effects of a 12-week VR fitness intervention on the
      functional fitness of adults of different age ranges.
    

Detailed description: 
      Previous studies have shown age-related decreases in physical activity and functional fitness
      among older adults. Virtual Reality (VR) exercise programs are currently used in leisure and
      entertainment to improve the physical health of older adults. However, VR exercise in
      assessing physical health or functional fitness in older adults of different age ranges is
      rare. To fill this research gap, VR exercise was to assess functional fitness improvement in
      young and middle-aged participants.
    

Intervention name(s): Virtual reality exercise intervention
Intervention type(s): Other
Intervention description(s): The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Keywords: Virtual reality; Exercise; Old adults
Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department
Condition: Pain
MeSH terms: Emergencies
Study type: Interventional

Summary: 
      The aims of this study are to assess efficacy and safety of patient-controlled analgesia
      (PCA) when applied to the Emergency Department setting and to compare the efficacy and safety
      of two PCA dosing regimens.
    

Detailed description: 
      The safety, efficacy, and dosing of PCA will be assessed in a randomized trial with three
      treatment arms:

        1. PCA with 1.0 mg morphine demand dosing every 6 minutes,

        2. PCA with 1.5 mg demand dosing every 6 minutes and

        3. a non-PCA comparison group.

      All patients will receive a loading dose of 0.1 mg/kg morphine. All patients can receive
      additional analgesics as needed, at the discretion of the provider.

      We hypothesize that morphine supplied via PCA will provide superior analgesia without a
      greater incidence of adverse events when compared to non-PCA pain management; and that PCA
      demand dosing of 1.5 mg will be superior to 1.0 mg without more adverse events.
    

Intervention name(s): Patient-controlled analgesia; morphine
Intervention type(s): Device; Drug
Intervention description(s): Intravenous morphine delivered via Curlin painsmart PCA device; Intravenous morphine
Other intervention name(s): PCA
Intervention MeSH terms: Morphine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Pain; Analgesia; Analgesia, Patient-controlled; Emergency Medicine
Feasibility Study: Higher Density Ulthera® System Treatment With Vectoring for Treatment of the Face and Neck
Condition: Skin Laxity
MeSH terms: Cutis Laxa
Study type: Interventional

Summary: 
      All enrolled subject will receive one Ultherapy™ treatment. Study images will be obtained
      pre-treatment, immediate post-treatment, and at each study follow-up visit. Enrolled subjects
      will return for follow-up visits at 90 days, 180 days and 365 days post-treatment.
    

Detailed description: 
      This is a prospective, single-center clinical trial to evaluate the efficacy of the Ulthera®
      System to provide a customized, high-density, vectored Ultherapy™ treatment to lift and
      tighten the skin of the face and neck. Skin laxity changes from baseline will be assessed at
      study follow-up visits. Global Aesthetic Improvement Scale scores and patient satisfaction
      questionnaires will also be obtained.
    

Intervention name(s): Ulthera System Treatment
Intervention type(s): Device
Intervention description(s): Focused ultrasound energy delivered below the surface of the skin
Other intervention name(s): Ultherapy™
Intervention model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Ulthera® System; Ultherapy™ Treatment; Ulthera, Inc.; Ultrasound treatment for skin tightening